Sumatriptan studies
Select the study ID number to view the trial summary
| Study ID | Phase | Title |
| 105817 | IV | A post-marketing surveillance study to monitor the safety of Imigran (sumatriptan) administered in Korean subjects according to the prescribing information. |
| SUM40260 | IV | Patient Preference for and Satisfaction With Migraine Therapy: IMITREX® Tablets Versus Pre-Study Non-Triptan Therapy. Imitrex is a registered trademark of GlaxoSmithKline. |
| EPI40050 | IV | The Sumatriptan and Naratriptan Pregnancy Registry |
| GL/MIG/017 | IV | A double-blind, placebo-controlled, crossover-designed study, to evaluate the efficacy of oral sumatriptan (100mg) in the acute treatment of perimenstrual migraine attacks. |
| S2B308E | IV | Evaluation of sumatriptan in the treatment of migraine pain recurrence- extension. |
| S2B350 | IV | Imitrex® Post-Marketing Surveillance Study. |
| S2BL36 Phase II | IV | A double-blind, placebo-controlled, parallel group study to evaluate the efficacy of subcutaneous GR43175C (6mg & optional 6mg) in the acute treatment of menstrual migraine – with optional open follow-up treatment. Phase II. |
| S2BL99 | IV | A randomised, multicentre, double-blind, double-dummy, parallel-group study to compare the efficacy and safety of subcutaneous sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. |
| S2BM01 | IV | A single-blind study to rechallenge patients who had previously experienced an adverse event involving discomfort or pain in the chest or throat following sumatriptan administration (SC or oral). Rechallenge outside of a migraine attack with subcutaneous sumatriptan 6mg. |
| S2BM02 | IV | An open-label study to rechallenge patients who had previously experienced an adverse event involving discomfort or pain in the chest or throat following sumatriptan administration (SC or oral). Rechallenge during a migraine attack with subcutaneous sumatriptan 6mg. |
| S2BM03 | IV | A double-blind, randomised, placebo controlled, crossover study to assess return of headache in patients treated with 6mg subcutaneous sumatriptan early or late in a migraine attack; with optional open-label doses to assess pattern of use of sumatriptan over the subsequent 72 hour period. |
| S2BM04 | IV | A double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety and tolerability of a 6mg sc dose of sumatriptan in patients who have not responded to acute treatment of a migraine attack with 100mg oral dose of sumatriptan. |
| S2BS75 | IV | A double-blind, placebo-controlled, parallel-group study of 6mg + optional 6mg subcutaneous GR43175C administered using the Glaxo Autoinjector in the treatment of a migraine attack, with an optional, open, 6-month extension: An interim report on the double-blind phase. |
| S2BS77 | IV | A double-blind, placebo-controlled, parallel group study of 6mg + optional 6 mg subcutaneous GR43175C (sumatriptan) administered using the Glaxo autoinjector during the aura phase of a migraine attack with an optional open six month extension. |
| S2BS78 | IV | A double-blind, placebo-controlled, parallel group study of 6mg subcutaneous sumatriptan + optional 6mg subcutaneous sumatriptan administered using a novel cartridge system self-injector in slow developing migraine. |
| SUM40019 | IV | A double blind, placebo-controlled, two-way cross-over study investigating the efficacy of Sumatriptan nasal spray in Children’s Migraine. |
| SUM40022 | IV | A randomised, controlled, partly crossover study of clinical efficacy, economic impact and quality of life of sumatriptan nasal spray (20mg) compared to patient’s customary treatment in acute migraine attacks in a workplace setting. |
| SUM40031 | IV | A randomised double-blind, double-dummy, single-attack, parallel group study to compare the speed of onset of sumatriptan nasal spray (20mg) with rizatriptan wafer (10mg) in the acute treatment of migraine. |
| SUM40254 | IV | A study to investigate the single dose pharmacokinetics of sumatriptan nasal spray in pediatric subjects outside a migraine attack |
| SUM40257 | IV | A randomised, multi-centre, open-label, crossover study to evaluate patient preference for sumatriptan 50mg and 100mg, naratriptan 2.5mg, rizatriptan 10mg and zolmitriptan 2.5mg tablets in the acute treatment of migraine. |
| SUM40265 | IV | A prospective multicentre study investigating the association between disability (as measured by the headache impact test, HIT-6) and IHS migraine classification (as determined by expert panel diary review) and to observe any changes in HIT-6 score following treatment with oral sumatriptan 50mg. |
| SUM40274 | IV | Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single-Attack Evaluation of Sumatriptan Tablets 50 mg and 100 mg Versus Placebo During a Migraine Headache at the First Sign of Pain. |
| SUM40275 | IV | Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single-Attack Evaluation of Sumatriptan Tablets 50 mg and 100 mg Versus Placebo During a Migraine Headache at the First Sign of Pain. |
| SUM40276 | IV | Final study report for protocol SUM40276 entitled “An open-label, long-term observational study of the safety and tolerability of sumatriptan nasal spray in the treatment of migraine in adolescents.” |
| SUM40282 | IV | A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of Sumatriptan 50mg and 100mg Tablets Administered During the Mild Pain Phase of a Menstrually-Associated Migraine Attack |
| SUM40285 | IV | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of Sumatriptan 50mg and 100mg Tablets Administered During the Mild Pain Phase of a Menstrually-Associated Migraine Attack |
| SUM40286 | IV | A randomized, double-blind, placebo-controlled, parallel-group, single-attack study of sumatriptan 6 mg injection in the treatment of moderate-to-severe migraine present upon awakening. |
| SUM40287 | IV | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single-Attack Study of Sumatriptan 6 mg Injection In the Treatment of Moderate-to-Severe Migraine Present Upon Awakening. |
| SUM40291 | IV | A randomized, double-blind, placebo-controlled, parallel-group, single-attack evaluation of sumatriptan 50mg and 100mg versus placebo during a migraine headache at the first sign of pain. |
| SUM40292 | IV | A randomised, multi-centre, single-blind, cross-over study to investigate the efficacy and safety of sumatriptan 25mg suppositories compared to naproxen 500mg suppositories in the acute, early treatment of migraine in patients suffering from nausea and/or vomiting during their attacks. |
| SUM40294 | IV | Identification of Migraine Headache Among Self-Described and/or Physician Diagnosed Sinus Headache Sufferers and Treatment with IMITREX† 50mg Tablets |
| SUM40298 | IV | A randomized, double-blind, placebo-controlled, single-attack, parallel-group evaluation of the efficacy of sumatriptan 50mg tablets versus placebo in the treatment of self-described and/or physician-diagnosed sinus headaches that meet International Headache Society (IHS) criteria for migraine headache. |
| SUM40299 | IV | A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and tolerability of oral sumatriptan 25mg, 50mg, and 100mg tablets for a single moderate or severe headache in adults diagnosed with migrainous disorder (IHS 1.7). |
| SUM40301 | IV | An open-label evaluation of patient satisfaction with IMITREX (sumatriptan succinate) tablets, 100mg, administered at the first sign of pain for up to three migraines in patients who are not satisfied with their current triptan therapy. |
| SUM40304 | IV | A randomised, double-blind, placebo controlled, cross-over clinical trial to investigate the relation of migraine recurrence and anxiety-depressive symptoms in patients treated with Sumatriptan. |
| SUM40308 | IV | A Danish, randomised, multicentre, comparative, parallel-group study of the effect of sumatriptan 50mg versus placebo in migraine patients with 6 to 11 attacks per year, taken during the mild phase of a migraine attack. |
| SUM40310 | IV | A randomised, open, parallel-group study comparing intake of sumatriptan 100mg tablets at the first signs of migraine pain versus intake at moderate to severe headache during an acute migraine attack |
| SUM40311 | IV | A randomized, double-blind, placebo-controlled, single-attack, parallel-group evaluation of the efficacy of sumatriptan 100mg tablets versus placebo in the treatment of self-described and/or physician-diagnosed sinus headaches that meet International Headache Society (IHS) criteria for migraine headache. |
| SUM40312 | IV | A Randomized, Double-Blind, Placebo-Controlled, Single-Attack, Parallel-Group Evaluation of the Efficacy of Sumatriptan 100mg Tablets versus Placebo in the Treatment of Subjects who Affirm Tension, Tension-Type or Stress Headaches and who meet International Headache Society (IHS) Criteria for Migraine. |
| SUMA4004 | IV | A randomized, double-blind, placebo-controlled study to evaluate the impact of Imitrex® injection on work place productivity loss due to migraine. Imitrex is a registered trademark of the GlaxoSmithKline group of companies. |
| SUMA4014 | IV | A Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy of a Second Sumatriptan Succinate Tablet (25 or 50mg) in the Acute Treatment of Migraine. |
| SUMA4015 | IV | A randomised, double-blind, placebo-controlled study to evaluate the impact of sumatriptan injection on work place productivity loss due to migraine. |
| SUMA4016 | IV | A Randomized, Double-Blind, Double-Dummy, Active-Placebo Controlled, Parallel Group Evaluation of Oral Sumatriptan (50mg) Compared to Oral Naproxen Sodium (275mg) on Migraine-Related Quality of Life. |
| SUMA4017 | IV | A Randomized, Double-Blind, Double-Dummy, Active-Placebo Controlled, Parallel Group Evaluation of Oral Sumatriptan (50mg) Compared to Oral Naproxen Sodium (275mg) on Migraine-Related Quality of Life. |
| SUMB4007 | IV | A double-blind, parallel group study to compare the benefits of 100mg and 50mg oral sumatriptan in patients dissatisfied with the relief of their migraine symptoms following open-label treatment with 50mg oral sumatriptan. |
| SUMT40 | IV | A crossover study to evaluate the efficacy and tolerability between sumatriptan suppository 25mg and sumatriptan tablet 50mg in the treatment of acute migraine (with and without aura) associated with the menstrual cycle. |
| GL/MIG/001/92 (Original Protocol) | III | A double-blind, general practice study to compare GR43175 with paracetamol and metoclopramide in the acute treatment of migraine. |
| GL/MIG/001A/92 (Amended Protocol) | III | A double-blind, general practice study to compare GR43175 with paracetamol and metoclopramide in the acute treatment of migraine. |
| GL/MIG/002 (Original protocol) | III | A double-blind general practice study to compare sumatriptan with MigraleveTM in the acute treatment of migraine. |
| GL/MIG/002A (Amended Protocol) | III | A double-blind general practice study to compare sumatriptan with MigraleveTM in the acute treatment of migraine. |
| GL/MIG/009 | III | A double blind study to compare acute sumatriptan with Migril in the treatment of migraine. |
| S2B210 | III | Efficacy of subcutaneous sumatriptan administered by the Glaxo autoinjector device- Protocol S2B210 |
| S2B211 | III | Efficacy of subcutaneous sumatriptan administered by the Glaxo autoinjector device- Protocol S2B211. |
| S2B301 (SUM30024) | III | Multicenter evaluation of the safety and efficacy of subcutaneous GR43175C in patients with acute migraine attacks. |
| S2B305 | III | Multi-center evaluation of the safety and efficacy of subcutaneous GR43175C in patients with acute migraine attacks – using a two-dose regimen. |
| S2B-307 | III | Repeat-dose efficacy and laboratory safety trial of subcutaneous GR43175C in migraine patients. |
| S2B308 | III | Evaluation of sumatriptan in the treatment of migraine pain recurrence- a pilot study. |
| S2B-340 | III | A double-blind, placebo-controlled, parallel group study to evaluate two dose levels (10mg and 20mg) of intranasal sumatriptan in the acute treatment of migraine attack. |
| S2B-341 | III | A double-blind, placebo-controlled, parallel group study to evaluate two dose levels (10mg and 20mg) of intranasal sumatriptan in the acute treatment of a migraine attack. |
| S2B-342 | III | A randomized, double-blind, placebo-controlled study to evaluate headache pain relief with sumatriptan nasal spray (5mg, 10mg, and 20mg) across three migraine attacks. |
| S2B-351 | III | A Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sumatriptan Suppositories in the Acute Treatment of a Single Migraine Attack. |
| S2B-352 | III | A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Safety and Efficacy of Sumatriptan Suppositories in the Acute Treatment of Three Migraine Attacks. |
| S2B-353 | III | A Randomized Double-Blind, Placebo-Controlled, Crossover Protocol to Evaluate the Safety and Efficacy of 12.5mg and 25mg Sumatriptan Suppository in the Treatment of Multiple Migraine Attacks. |
| S2BL36 Phase I | III | A double-blind, placebo-controlled, parallel group study to evaluate the efficacy of subcutaneous GR43175C (6mg & optional 6mg) in the acute treatment of menstrual migraine – with optional open follow-up treatment: Phase I. |
| S2BS70 | III | Evaluation of up to two oral doses of sumatriptan (100mg) following acute treatment of migraine with subcutaneous sumatriptan (6mg). |
| S2BT27 | III | A double-blind study to compare oral GR43175C (100mg) with oral aspirin (900mg) plus metoclopramide (10mg) in the acute treatment of migraine over a six month period. |
| S2BT33 | III | An open design study to evaluate repeat-dose oral sumatriptan (100 mg plus optional 100 mg plus optional further 100 mg for recurrent headache) in the acute treatment of migraine attacks during a 24-month period. |
| S2BT38 | III | The acute treatment of cluster headache with subcutaneous GR43175C (6mg and 12mg) – a double-blind, placebo-controlled, dose-comparison, crossover study. |
| S2BT42 | III | An open design, multiple treatment study to evaluate subcutaneous sumatriptan (6mg) in the acute treatment of cluster headache attacks during a 3-month period. |
| S2BT50 (SUMB3002) | III | A double-blind, placebo-controlled, parallel-group study to evaluate two dose levels (10mg and 20mg) of sumatriptan nasal spray in the acute treatment of a migraine attack with an optional repeat dose for headache recurrence |
| S2BT55 | III | A double-blind, placebo-controlled, parallel-group study to evaluate two dose levels of sumatriptan suppository (12.5mg and 25mg) in the acute treatment of migraine attack, with an optional repeat dose for headache recurrence |
| S2BT56 | III | A randomised, double-blind, cross-over study to compare the efficacy and safety of sumatriptan 25mg suppository with cafergot suppository (2mg ergotamine tartrate, 100mg caffeine) (one suppository plus option of one additional suppository) in the acute treatment of migraine. |
| S2BT57 | III | An open design study to evaluate the safety of rectal dosing with sumatriptan (25mg and optional 25mg dose for headache recurrence) in the acute treatment of all migraine attacks over a 12 month period. |
| S2BT60 | III | A randomised, double-blind, double-dummy, cross-over study to compare the efficacy and safety of sumatriptan nasal spray (20mg) with dihydroergotamine (DHE) nasal spray (1mg plus optional 1mg) in the acute treatment of migraine. |
| S2CM07 | III | A double-blind placebo controlled study to assess the efficacy/safety of oral sumatriptan (50mg film coated tablet) in the acute treatment of migraine with an optional second dose to treat recurrence. |
| S2CM11 | III | A double-blind, crossover study to assess patient preference, efficacy and safety of oral sumatriptan (25mg, 50mg and 100mg film-coated tablets) in the acute treatment of migraine. |
| S2CT34 | III | A double-blind study to compare the efficacy of a repeat dose of oral GR43175C regimen (plus a further optional dose for recurrence) with placebo in the acute treatment of migraine. |
| S2CT37 | III | A double-blind study to compare the efficacy and safety or oral sumatriptan (50mg or 100mg) with placebo for the acute treatment of migraine in adolescents. |
| S2CT40 | III | A double-blind study to compare the efficacy and safety of oral sumatriptan (50mg or 100mg) with placebo for the acute treatment of migraine in adolescents. |
| S2CT41 | III | Pre-emptive oral GR43175C treatment during a cluster headache period – (100mg tid for 7 days) – A double-blind, parallel group, placebo controlled study. |
| SMT-06-91 | III | Double blind, placebo-controlled, cross-over study to assess the safety and efficacy of repeated oral doses of sumatriptan (GR43175C) 100mg (plus two optional oral doses of sumatriptan (GR43175C) 100mg) in the acute treatment of migraine. |
| SUM S2BL 25 | III | Subcutaneous sumatriptan in the acute treatment of migraine in patients using dihydroergotamine as prophylaxis. |
| SUM30009 | III | A single centre, placebo-controlled, double blind, randomised cross-over, single attack study evaluating the efficacy and tolerability of sumatriptan nasal spray 10mg for the acute treatment of migraine in children suffering from refractory migraine with/without aura. |
| SUM30017 (Protocol Number S2BT26) | III | A double-blind study to compare oral GR43175C (100mg) with oral aspirin (900mg) and metoclopramide (10mg) in the acute treatment of migraine. |
| SUM30018 (Protocol Number S2BT25) | III | A double-blind study to compare oral GR43175C with oral Cafergot (ergotamine + caffeine) in the acute treatment of migraine. |
| SUM30023 (S2BT28) | III | A double-blind study to compare the efficacy of subcutaneous GR43175C with that of subcutaneous placebo injection in the acute treatment of migraine. |
| SUM30029 (S2BT51) | III | An open design study to evaluate the efficacy and tolerability of sumatriptan nasal spray (20mg + optional 20mg dose for headache recurrence) in the acute treatment of migraine during a 12 month period. |
| SUM30042 | III | A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Cross-Over Study to Investigate the Efficacy, Safety and Tolerability of Sumatriptan Nasal Spray (10mg or 20mg) in the Treatment of Acute Migraine in Patients Aged 12-17. |
| SUM30045 | III | A Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate Two Dose Levels (5mg And 20mg) Of Sumatriptan Nasal Spray In The Acute Treatment Of A Single Migraine Attack In Adolescent Migraineurs (12-17 Years Of Age) |
| SUM30046 | III | A randomised, double-blind, single-attack, placebo-controlled, parallel group evaluation of the efficacy and tolerability of sumatriptan Fast Disintegrating Tablets (FDT) 50 mg and 100 mg versus placebo during the mild pain phase of a migraine attack. |
| SUM30047 | III | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single-Attack Study to Evaluate the Onset of Efficacy of a New Formulation of Sumatriptan Tablets 50mg and 100mg in the Acute Treatment of Migraine |
| SUM30053 | III | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single-Attack Study to Evaluate the Onset of Efficacy of a New Formulation of Sumatriptan Tablets 50mg and 100mg in the Acute Treatment of Migraine (EU study). |
| SUM40090 | III | The use of oral sumatriptan on compassionate grounds for the acute treatment of migraine in adolescent patients (ages 12 to 17). |
| SUMA3005 | III | A double-blind. placebo-controlled, parallel group study to evaluate three dose levels (5mg, 10mg and 20mg) of sumatriptan nasal spray in the acute treatment of a single migraine attack in adolescent migraineurs (12-17 years of age). |
| SUMA3006 | III | An open-label study to evaluate the long-term safety, tolerability and efficacy of sumatriptan nasal spray in the acute treatment of multiple migraine attacks in adolescent migraineurs (12-17 years of age). |
| SUMAI 01 | III | An open 6-month-study for the treatment of acute migraine attacks with sumatriptan (6 mg subcutaneous (sc). plus optional 6 mg sc) using an autoinjector, complemented by a) the possibility to prolong the study up to 18 months in total; and/or complemented by b) the possibility to assess quality of life |
| SUMAI CH | III | An open 12-month study for the acute treatment of cluster headache attacks with sumatriptan using an autoinjector. |
| SUMB3005 | III | An open-label study to evaluate repeat-dose oral sumatriptan 100mg in the acute treatment of adolescent migraine during a six month period. |
| SUMT37 | III | Efficacy and tolerability of oral sumatriptan 50mg, as acute treatment for mild to moderate migraine, in patients not responders to common analgesics or anti-inflammatories. |
| RES20044 | II | A double-blind, randomised, single dose, placebo-controlled, crossover design to investigate the efficacy of a new chemical entity (NCE) administered intravenously and subcutaneous sumatriptan in acute migraine. |
| S2B-201 | II | Evaluation of the safety and efficacy of subcutaneous GR43175C in migraine patients |
| S2B206 | II | Dose range trial of oral GR43175C in migraine patients. |
| S2B216 | II | Safety and efficacy of three doses of GR43175C in acute migraine treatment. |
| S2B-306 (SUM30020) | II | Multi-center evaluation of the safety and efficacy of subcutaneous GR43175C in patients with acute migraine attacks – using a two-dose regimen. |
| S2B310 (SUM40130) | II | Evaluation of a combined regimen of subcutaneous and oral GR43175C in the prevention of migraine recurrence. |
| S2BP31 | II | The treatment of chronic tension-type headache with subcutaneous GR43175C – a placebo-controlled dose-comparison study. |
| S2BP42 | II | A single-blind two-part study to rechallenge with subcutaneous GR43175C, patients who had previously experienced an adverse event involving discomfort or pain in the chest following GR43175C administration. |
| S2BT02 | II | The acute treatment of migraine with subcutaneous GR43175C. A placebo-controlled, dose-comparison, multicentre, multinational study. |
| S2BT02 Addendum | II | Open, additional treatment with GR43175C by subcutaneous injection for patients participating in protocol S2BT02. |
| S2BT03 | II | The acute treatment of migraine with oral GR43175C: a placebo-controlled dose comparison, multicentre, multinational study. |
| S2BT16 | II | A double-blind, placebo-controlled, crossover study to evaluate oral GR43175C 100 mg in the acute treatment of migraine. |
| S2BT23 | II | A double-blind, placebo-controlled cross-over study to evaluate the acute effects of subcutaneous GR43175C (6mg) in cluster headache. |
| S2BT35 | II | A double-blind, placebo-controlled study to evaluate intranasal GR43175N (1mg, 5mg, 10mg, 20mg and 40mg) in the acute treatment of migraine (one nostril application). |
| S2BT39 | II | A double-blind, placebo-controlled study to evaluate intranasal GR43175N (1, 5, 10, 20 and 40mg) in the acute treatment of migraine (two-nostril application). |
| S2BT47 | II | A double-blind, placebo-controlled, parallel group study to evaluate four dose levels of sumatriptan intranasal (2.5, 5, 10, 20mg) in the acute treatment of migraine. |
| S2BT49 | II | A double-blind, placebo-controlled, randomised, parallel group study to evaluate 5 dose levels of sumatriptan suppositories (6, 12.5, 25, 50 and 100mg) in the acute treatment of migraine. |
| S2CM09 | II | A double-blind, placebo-controlled study to compare the efficacy and safety of oral sumatriptan (25mg, 50mg and 100mg film-coated tablets) in the acute treatment of migraine with an optional second dose to treat recurrence. |
| S2CP46 | II | An in-clinic pilot study to examine the efficacy and safety of oral GR43175C (50mg or 100mg) for the acute treatment of migraine in adolescents. |
| S2CP81 | II | The acute treatment of episodic tension-type headache with oral GR43175C (100mg) – a double-blind, placebo-controlled, parallel group pilot study. |
| SUM20018 (S2BT20) | II | The acute treatment of migraine with subcutaneous GR43175C. A placebo-controlled study. |
| SUM20033 | II | A Randomised, Double-Blind, Placebo-Controlled, In-Clinic Pilot Study To Investigate The Efficacy And Tolerability Of 100mg Sumatriptan Administered As A Film-Coated, Fast Disintegrating Tablet |
| SUM40135 (S2CS01) | II | A double-blind, placebo-controlled, parallel-group study of a second 100mg oral dose of GR43175C in the acute treatment of a migraine attack and of a further 100mg dose in treating headache recurrence. |
| SUM40255 | II | Open, pilot study to evaluate the efficacy, tolerability and safety of a combination of sumatriptan oral (50mg) + oral metoclopramide (10mg) + oral aspirin (900mg) in the treatment of a single migraine attack in patients not usually pain free during previous attacks, with the following molecules, taken by oral route as monotherapy: triptan and aspirin. |
| SUMA2002 | II | A randomized, double-blind, placebo-controlled study of the safety and efficacy of 25mg, 50mg and 100mg oral sumatriptan in adolescent migraine subjects. |
| SUMB2003 | II | A double-blind, randomised, placebo-controlled study to compare the efficacy and safety of oral sumatriptan (25mg, 50mg and 100mg) in the acute treatment of migraine in adolescents. |
| AMI02 | I | Phase I study (repeated dose) of sumatriptan intranasal spray. |
| C92-050 | I | A study to determine whether the pharmacokinetics, safety or tolerability of subcutaneously administered sumatriptan (6 mg) are altered by interaction with concurrent oral monoamine oxidase inhibitors. |
| C92-051 | I | A study to investigate the effect of sumatriptan on oesophageal motor function and gastroesophageal reflux. |
| C93-025 | I | A study to investigate intra-subject variability and sex differences in the pharmacokinetics of 100mg sumatriptan following oral dosing. |
| C93-078 | I | A study to investigate the effect of oral sumatriptan on the intraocular pressure of healthy subjects. |
| C94-016 | I | A study to investigate the effect of 6mg subcutaneous sumatriptan on oesophageal motility. |
| C94-057 | I | A study to investigate the effects of the monoamine oxidase A inhibitor, moclobemide, on the pharmacokinetics, safety and tolerability of oral sumatriptan. |
| S2B103 | I | Evaluation of the pharmacokinetics and safety of ascending doses of GR43175C administered subcutaneously to healthy male volunteers. |
| S2B-107 | I | Evaluation of the pharmacokinetics and safety of ascending oral doses of GR43175C administered to healthy male volunteers. |
| S2B110 | I | Tolerance assessment of daily subcutaneous (sc) GR43175C. |
| S2B-121 | I | Evaluation of the Anatomic Site of Absorption of Sumatriptan (GR43175). |
| S2B-124 | I | A Study to Evaluate the Bioequivalence of 50 and 100mg Sumatriptan Tablets. |
| S2B125 | I | A study to evaluate the safety, tolerability and pharmacokinetics of sumatriptan (GR43175) following repeat administration intranasally. |
| S2B-199 | I | The evaluation of electrocardiograms following a single 100mg oral dose of GR43175C administered to healthy male volunteers. |
| S2B203 | I | Evaluation of the effect of GR43175C on blood pressure in hypertensive migraine patients. |
| S2B222 | I | A study to investigate the effects of subcutaneous GR43175C on the coronary vasculature in patients with existing or suspected coronary artery disease. |
| S2B-H27 | I | A study to determine whether ergotamine (0.25mg given intravenously) has any effect on the pharmacodynamics and pharmacokinetics of GR43175C in healthy subjects. |
| S2BP33 | I | A study to investigate the effects on the coronary vasculature of the 5HT1-like receptor agonist, GR43175C, in subjects with existing coronary artery disease. |
| S2BP49 | I | A study to investigate the effects of subcutaneous GR43175C on the coronary vasculature in patients with existing or suspected coronary artery disease |
| S2BP55 | I | A study to investigate the effects of subcutaneous sumatriptan on cardiac haemodynamics in patients with existing or suspected coronary artery disease. |
| SUM01 | I | A study to evaluate the excretion of a 6mg subcutaneous dose of sumatriptan into breast milk. |
| SUM102146 | I | An open-label, randomized, three-period crossover study to demonstrate the bioequivalence of sumatriptan 4 mg STATdose to IMITREX™ 6 mg STATdose after dose-normalization, and to assess the relative bioavailability of 4 mg sumatriptan injected using the STATdose device compared to 4 mg sumatriptan injected manually. |
| SUM10923 (C93-053) | I | A study to assess the pharmacokinetic and pharmacodynamic profile of intranasal sumatriptan at doses of 5 mg, 10 mg and 20 mg. |
| SUM10948 | I | An open, randomised, single-dose, three-way crossover, pilot study investigating the relative bioavailability of two newly formulated fast disintegrating sumatriptan 50mg tablets versus the currently marketed sumatriptan 50mg tablets in healthy volunteers |
| SUM10950 | I | An open, randomised, four-period crossover study to demonstrate the bioequivalence of fast disintegrating sumatriptan tablets (50 and 100 mg tablets) compared with the currently marketed sumatriptan tablets (50 and 100 mg IMITREX† /IMIGRAN† tablets), in healthy male and female volunteers |
| SUM10954 | I | An open, randomised, three-period crossover study to demonstrate the bioequivalence of fast disintegrating sumatriptan 100 mg tablet compared to the currently marketed sumatriptan 100 mg tablet administered immediately after food and the fast disintegrating tablet administered in the fasted state to healthy male and female subjects |
| SUM10955 | I | An open, randomised, four-period crossover study to investigate the bioavailability of a new orally disintegrating (melt) formulation (ODT) of sumatriptan, with and without water compared to the currently marketed sumatriptan 100 mg tablet and also to investigate the effect of food on the ODT formulation, in healthy male and female subjects. |
| SUM10961 | I | An open, randomised, two-period crossover study to demonstrate the bioequivalence of fast disintegrating sumatriptan 100 mg tablet dissolved in water compared to the currently marketed sumatriptan 100 mg tablet administered in the fasted state to healthy male and female subjects |
| SUM20040 | I | An open-label, randomised, two-period, crossover study to assess the safety, tolerability and pharmacokinetics of the 3 mg STATdose administered two hours after a single IMITREX 100 mg tablet relative to two 6 mg STATdose injections administered one hour apart in healthy volunteers. |
| SUM40026 | I | Double-blind, randomised, placebo-controlled, four period cross-over comparative study on CNS effects of two oral doses separated by 2 hours of rizatriptan (2x10mg), sumatriptan (2x50mg), an active comparator temazepam (placebo followed by 20mg two hours later) and placebo in healthy female subjects, and in migraineurs outside of an attack. |
| SUM40029 | I | Pharmacokinetics and user acceptability of Intraject sumatriptan vs GW auto-injector (Subject, Self or Statdose) in migraine patients outside of an attack. |
| SUM40036 and SUM-PK001 | I | A study of the pharmacokinetics and bioequivalence of the Japanese and GWUK market formulations of sumatriptan succinate performed in Japanese and Caucasian populations. |
| SUM40252 | I | An open, randomized, three-way crossover study in healthy subjects to evaluate the bioequivalence and taste acceptability of two different 20mg/100µL sumatriptan nasal spray formulations compared to the current 20mg/100µL sumatriptan nasal spray market formulation following single dose administration. |
| SUM40272 | I | An open-label, randomized, cross-over study to investigate the potential pharmacokinetic interaction of sumatriptan and clarithromycin when co-administered to healthy volunteers. |
| SUM40273 | I | An open-label study to investigate the potential pharmacokinetic interaction of sumatriptan and an oral contraceptive when co-administered to healthy volunteers. |
| SUMB1006 | I | An open, uncontrolled study to investigate the single dose pharmacokinetics of sumatriptan nasal spray in adolescent subjects with migraine outside of a migraine attack. |
| SUMB2001 | I | A double-blind, randomised, placebo-controlled study to investigate the neuroendocrine response to repeat-dose oral sumatriptan in adolescent migraineurs. |
| W91-009 | I | A study to compare the pharmacokinetics of single oral and subcutaneous doses of sumatriptan in patients with hepatic impairment and in healthy subjects. |
| WHP:86:34 | I | A preliminary study to investigate the safety, tolerability and pharmacokinetics of intranasally administered GR43175N in 6 healthy male volunteers. |
| WHP:86:38 | I | GR43175 base plasma levels after single oral doses (dispersible tablets) of 70mg, 140mg and 280mg GR43175 base (as succinate) in 6 healthy volunteers. |
| WHP:88:16 | I | The effect of two consecutive doses of GR43175N, administered as an intranasal spray, on peak plasma drug levels |
| WHP:88:20 | I | To determine the effect of food on the pharmacokinetics of oral GR43175C |
| WHP:88:34 | I | To examine the pharmacokinetics, safety and tolerability of repeat oral dosing with GR43175C. |
| WHP:88:35 | I | The safety, tolerability and pharmacokinetics of two oral doses of GR43175C separated by two hours. |
| WHP:88:81 | I | To determine whether propranolol has any effect on the pharmacokinetics or pharmacodynamics of oral G43175C in healthy subjects. |
| WHP:88:82 | I | A pilot study to evaluate the effect of GR43175C on gastric emptying in healthy subjects. |
| WHP:88:83 | I | A study to investigate any interaction between pizotifen and GR43175C |
| WHP:88:84 | I | A study to determine whether flunarizine has any effect on the pharmacokinetics and pharmacodynamics of oral G43175C in healthy subjects |
| WHP:89:08 | I | A study to investigate the tolerance of subcutaneous injection with GR43175C at concentrations of 12, 16 and 24 mg/mL |
| WHP:89:10 | I | A study to investigate the pharmacokinetics of GR43175C after four different oral doses. |
| WHP:89:11 | I | A study to determine whether alcohol has any effect on the pharmacokinetics or pharmacodynamics of GR43175C administered orally. |
| WHP:89:12 | I | An assessment of the pharmacokinetics and local site irritancy after subcutaneous administration of GR43175C using a standard subcutaneous injection technique and an autoinjector. |
| WHP:89:18 | I | An investigation into the effects of single oral doses of GR43175C on psychomotor function in healthy subjects. |
| WHP:89:19 | I | A pilot study to investigate safety and tolerability of subcutaneously administered GR43175C in the elderly. |
| WHP:89:30 | I | A study to monitor blood pressure after administration of oral GR43175C in young and elderly subjects. |
| WHP8625 | I | A preliminary study to investigate the safety, tolerability and pharmacokinetics of intramuscularly administered GR43175C in three healthy male volunteers. |
| WHP8880 | I | A study to investigate the absolute bioavailability of subcutaneous and oral GR43175C. |